Rodrigo Cavallazzi is a Respiratory physician affiliated with University of Louisville. OpenAlex indexes 191 publications with 7,508 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
401 E Chestnut Street, #310
University Medical Associates
Louisville, KY 402025703
Telephone
502-589-6788Provider last certified this registry record 23 Jan 2020.
Clinical trials
- Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)
Sponsor: University of Louisville
- PAV vs Assist Control After Failed SBT
Sponsor: University of Louisville
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Electromed, Inc.Program year20253 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- Ethicon Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
85.9%Corticosteroid35.5%Trelegy Ellipta26%Fluticasone Propionate26%Breo Ellipta12%Symbicort10%Breztri Aerosphere9%Budesonide-Formoterol Fumarate8%Dulera5%Breyna4%Part D<11 patientsbeta2-Adrenergic Agonist28.4%Albuterol Sulfate Hfa91%Ventolin Hfa9%Part D≥81 patients+ 4 more classes in this area
Metabolism & gastrointestinal
5.6%Corticosteroid4.7%Prednisone100%Part D≥28 patientsProton pump inhibitor0.8%Pantoprazole Sodium100%Part D<11 patientsAnti-infectives
4.6%Macrolide Antimicrobial2.1%Azithromycin100%Part D<11 patientsTetracycline-class Drug1.7%Doxycycline Hyclate100%Part D≥16 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Community-Acquired Pneumonia in the Immunocompromised Host: Epidemiology and Outcomes
Open Forum Infectious Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Kelly McMasters, MD
University of Louisville
Stephen McClave, MD
University of Louisville
Robert Friedland, MD
University of Louisville
Charles Scoggins, MD
University of Louisville
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”